Telomir Pharmaceuticals Inc (TELO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.160.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TELO
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Progress the Phase 1/2 clinical trial of Telomir-Zn targeting epigenetic and metabolic drivers in TNBC, supported by peer-reviewed preclinical data.
Stated as a priority in 2 of last 2 quarters. Management highlighted peer-reviewed preclinical publications demonstrating Telomir-Zn's tumor suppression and anti-metastatic effects in TNBC models and confirmed FDA IND clearance for Phase 1/2 clinical trials in 2026-Q1. The trajectory is delivering with clinical trial preparations underway.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Not enough signal yet.
Over the trailing year it converted 0.30x of net income into operating cash flow.
Not enough signal yet.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Publication supports advancement of Telomir-Zn toward Phase 1/2 clinical trial in TNBC.”
“Received FDA IND clearance for Phase 1/2 clinical trial in advanced or metastatic TNBC.”
Finalize the acquisition of TELI Pharmaceuticals and integrate its assets to enhance Telomir's pipeline and capabilities.
Stated in 2 of last 2 quarters. The acquisition of TELI Pharmaceuticals was completed in April 2026 as announced, with shareholder approval obtained earlier. Management has focused on integration since completion. The trajectory shows completion and ongoing integration efforts.
“Completed acquisition of TELI Pharmaceuticals in April 2026.”
“Discussed acquisition agreement and shareholder approval for TELI Pharmaceuticals.”
Publish preclinical data validating Telomir-Zn's mechanism and therapeutic potential across multiple disease models.
Stated in 3 quarters including 2026-Q2, 2026-Q1, and an undated 2026 publication. Management has consistently published peer-reviewed studies validating Telomir-Zn's mechanism across cancer, Wilson's disease, and diabetes models. This recurring focus shows steady delivery of scientific evidence supporting the platform.
“Published peer-reviewed study on Telomir-Zn suppressing tumor growth in TNBC and prostate cancer.”
“Published peer-reviewed data showing survival improvement in Wilson's disease model.”
Manage financial resources prudently while operating at a net loss and negative cash flow from operations.
Stated as a priority in 6 of last 6 quarters. The company reported net losses each quarter, ranging from negative $5.1M in 2025-Q2 to negative $1.7M in 2026-Q2, with negative cash flow from operations consistently between $0.7M and $1.77M. Management's emphasis on capital discipline aligns with ongoing operational losses, indicating mixed progress in managing financial resources.
“Net income was negative $1.7M with cash from operations negative $1.0M.”
“Net income negative $0.99M and cash from operations negative $1.77M.”
“Net income negative $2.1M and cash from operations negative $1.2M.”
“Net income negative $1.1M and cash from operations negative $0.93M.”
“Net income negative $5.1M and cash from operations negative $0.7M.”
“Net income negative $2.2M and cash from operations negative $0.86M.”
Address changes in executive leadership including CFO departure and appointment of fractional CFO.
Newly stated in 2026-Q2. Management reported the CFO departure and subsequent fractional CFO appointment in June 2026. This is a recent development with limited historical recurrence, reflecting active management of leadership transitions.
“CFO departure and appointment of fractional CFO noted without disagreement.”
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
26 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.